Princess Maxima Center For Pediatric Oncology

This study tests a drug called blinatumomab in infants under 1 year old who have a specific, hard-to-treat type of leukemia (KMT2A-rearranged). The goal is to improve how long these babies stay cancer-free and to help them live longer. About 160 infants will take part, and the tr…

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is. About 6…

This study tests a combination of two targeted drugs (dasatinib and venetoclax) plus chemotherapy in children and young adults up to age 21 whose leukemia or lymphoma has come back or not responded to treatment. The goal is to find the safest dose and see how well the drugs shrin…

This study tests a combination of the targeted drug trametinib with standard chemotherapy drugs (dexamethasone, cyclophosphamide, and cytarabine) in children and young adults up to age 21 whose leukemia or lymphoma has returned or not responded to treatment. The goal is to find t…

This study brings together a team of specialists across Europe to review each child's unique cancer genetics and recommend the most promising treatment from available options. It includes 600 children and young adults up to age 25 with relapsed or hard-to-treat blood cancers. The…